{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:53:39Z","timestamp":1767149619745,"version":"build-2238731810"},"reference-count":35,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":60,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis Imaging"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ostima.2022.100082","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:10:56Z","timestamp":1668557456000},"page":"100082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Inter-reader consistency and exclusionary findings during radiographic screening for Phase 3 trials of tanezumab in patients with osteoarthritis"],"prefix":"10.1016","volume":"2","author":[{"given":"Ali","family":"Guermazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank W.","family":"Roemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Kompel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis E.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel D.","family":"Crema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark T.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn C.","family":"Pixton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Viktrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Fountaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee","family":"Burr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5351-3828","authenticated-orcid":false,"given":"Sarah P.","family":"Sherlock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine R.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ostima.2022.100082_bib0001","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2147\/JPR.S247472","article-title":"Nerve growth factor signaling and its contribution to pain","volume":"13","author":"Barker","year":"2020","journal-title":"J. Pain Res."},{"issue":"10","key":"10.1016\/j.ostima.2022.100082_bib0002","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1097\/j.pain.0000000000001625","article-title":"Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety [review]","volume":"160","author":"Schmelz","year":"2019","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.ostima.2022.100082_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2131\/jts.43.1","article-title":"Development of pain therapies targeting nerve growth factor signal transduction and the strategies used to resolve safety issues [review]","volume":"43","author":"B\u00e9langer","year":"2018","journal-title":"J. Toxicol. Sci."},{"issue":"10","key":"10.1016\/j.ostima.2022.100082_bib0004","first-page":"697","article-title":"Painkilling anti-NGF antibodies stage phase III comeback","volume":"17","author":"Mullard","year":"2018","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"107","key":"10.1016\/j.ostima.2022.100082_bib0005","first-page":"85","article-title":"Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain [review]","volume":"35","author":"Miller","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ostima.2022.100082_bib0006","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3389\/fphar.2020.00817","article-title":"The efficacy of nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: a meta-analysis","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ostima.2022.100082_bib0007","article-title":"Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies","volume":"23","author":"Hochberg","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.ostima.2022.100082_bib0008","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research Summary Minutes of the Arthritis Advisory Committee Meeting March 12, 2012 https:\/\/wayback.archive-it.org\/7993\/20170404145629\/https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ArthritisAdvisoryCommittee\/UCM307879.pdf (accessed 7th August 2020)."},{"issue":"3","key":"10.1016\/j.ostima.2022.100082_bib0009","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.semarthrit.2017.05.008","article-title":"Development of an imaging mitigation strategy for patient enrolment in the tanezumab nerve growth factor inhibitor (NGF-ab) program with a focus on eligibility assessment","volume":"47","author":"Roemer","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.ostima.2022.100082_bib0010","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.joca.2014.09.015","article-title":"Imaging atlas for eligibility and on-study safety of potential knee adverse events in anti-NGF studies (Part 1)","volume":"23","author":"Roemer","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"issue":"1","key":"10.1016\/j.ostima.2022.100082_bib0011","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.joca.2014.09.014","article-title":"Imaging atlas for eligibility and on-study safety of potential hip adverse events in anti-NGF studies (Part 2)","volume":"23","author":"Roemer","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"issue":"1","key":"10.1016\/j.ostima.2022.100082_bib0012","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.joca.2014.09.018","article-title":"Imaging atlas for eligibility and on-study safety of potential shoulder adverse events in anti-NGF studies (Part 3)","volume":"23","author":"Roemer","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.ostima.2022.100082_bib0013","doi-asserted-by":"crossref","unstructured":"Pfizer, Pfizer reports third-quarter 2021 results. 2021.","DOI":"10.1016\/j.fopow.2021.11.012"},{"key":"10.1016\/j.ostima.2022.100082_bib0014","doi-asserted-by":"crossref","unstructured":"Company, E.L.a., Lilly reports robust third-quarter 2021 financial results as pipeline success strengthens future growth potential. 2021.","DOI":"10.1016\/j.fopow.2021.11.012"},{"issue":"1","key":"10.1016\/j.ostima.2022.100082_bib0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2019.8044","article-title":"Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial","volume":"322","author":"Schnitzer","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ostima.2022.100082_bib0016","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/annrheumdis-2019-216296","article-title":"Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period","volume":"79","author":"Berenbaum","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ostima.2022.100082_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/art.41674","article-title":"Long-term safety and efficacy of subcutaneous tanezumab versus nonsteroidal antiinflammatory drugs for hip or knee osteoarthritis: a randomized trial","author":"Hochberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ostima.2022.100082_bib0018","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jor.2020.11.014","article-title":"Spontaneous osteonecrosis of the knee (SONK): the role of MR imaging in predicting clinical outcome","volume":"22","author":"Husain","year":"2020","journal-title":"J. Orthop."},{"issue":"3","key":"10.1016\/j.ostima.2022.100082_bib0019","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1148\/radiol.2020200771","article-title":"Intra-articular corticosteroid injections for the treatment of hip and knee osteoarthritis-related pain: considerations and controversies with a focus on imaging\u2014radiology scientific expert panel","volume":"297","author":"Guermazi","year":"2020","journal-title":"Radiology"},{"issue":"9","key":"10.1016\/j.ostima.2022.100082_bib0020","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.joca.2009.03.012","article-title":"MRI-detected subchondral bone marrow signal alterations of the knee joint: terminology, imaging appearance, relevance and radiological differential diagnosis [review]","volume":"17","author":"Roemer","year":"2009","journal-title":"Osteoarthritis Cartilage"},{"issue":"1","key":"10.1016\/j.ostima.2022.100082_bib0021","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.ostima.2022.100082_bib0022","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0037-1602249","article-title":"Inter- and Intraobserver reliabilities of four different radiographic grading scales of osteoarthritis of the Knee Joint","volume":"31","author":"Kose","year":"2018","journal-title":"J. Knee Surg."},{"issue":"10","key":"10.1016\/j.ostima.2022.100082_bib0023","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s00256-021-03767-y","article-title":"Inter- and intra-observer reliability of radiological grading systems for knee osteoarthritis","volume":"50","author":"Eckersley","year":"2021","journal-title":"Skeletal Radiol."},{"key":"10.1016\/j.ostima.2022.100082_bib0024","doi-asserted-by":"crossref","first-page":"h5983","DOI":"10.1136\/bmj.h5983","article-title":"Association of hip pain with radiographic evidence of hip osteoarthritis: diagnostic test study","volume":"351","author":"Kim","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.ostima.2022.100082_bib0025","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2474-9-116","article-title":"The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature [review]","volume":"9","author":"Bedson","year":"2008","journal-title":"BMC Musculoskelet. Disord."},{"issue":"2","key":"10.1016\/j.ostima.2022.100082_bib0026","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.34646","article-title":"Discordance between pain and radiographic severity in knee osteoarthritis: findings from quantitative sensory testing of central sensitization","volume":"65","author":"Finan","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.ostima.2022.100082_bib0027","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/art.1780340502","article-title":"The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip","volume":"34","author":"Altman","year":"1991","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.ostima.2022.100082_bib0028","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.1780290816","article-title":"Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association","volume":"29","author":"Altman","year":"1986","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ostima.2022.100082_bib0029","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/03009748709102175","article-title":"Criteria for the classification of osteoarthritis of the knee and hip","volume":"65","author":"Altman","year":"1987","journal-title":"Scand. J. Rheumatol. Suppl."},{"issue":"suppl_4","key":"10.1016\/j.ostima.2022.100082_bib0030","doi-asserted-by":"crossref","first-page":"iv51","DOI":"10.1093\/rheumatology\/kex501","article-title":"What is the role of imaging in the clinical diagnosis of osteoarthritis and disease management? [review]","volume":"57","author":"Wang","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ostima.2022.100082_bib0031","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2012-202231","article-title":"Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial","volume":"72","author":"Reginster","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.ostima.2022.100082_bib0032","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.joca.2014.12.019","article-title":"Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials","volume":"23","author":"Karsdal","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"issue":"3","key":"10.1016\/j.ostima.2022.100082_bib0033","doi-asserted-by":"crossref","DOI":"10.1186\/ar1716","article-title":"Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]","volume":"7","author":"Spector","year":"2005","journal-title":"Arthritis Res. Ther."},{"issue":"14","key":"10.1016\/j.ostima.2022.100082_bib0034","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2019.14735","article-title":"Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial","volume":"322","author":"Hochberg","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ostima.2022.100082_bib0035","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/annrheumdis-2012-202239","article-title":"A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee","volume":"72","author":"Hellio le Graverand","year":"2013","journal-title":"Ann. Rheum. Dis."}],"updated-by":[{"DOI":"10.1016\/j.ostima.2024.100253","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000}}],"container-title":["Osteoarthritis Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772654122000812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772654122000812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:00:06Z","timestamp":1757419206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772654122000812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":35,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2772654122000812"],"URL":"https:\/\/doi.org\/10.1016\/j.ostima.2022.100082","relation":{},"ISSN":["2772-6541"],"issn-type":[{"value":"2772-6541","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inter-reader consistency and exclusionary findings during radiographic screening for Phase 3 trials of tanezumab in patients with osteoarthritis","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ostima.2022.100082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd on behalf of International Society of Osteoarthritis Imaging.","name":"copyright","label":"Copyright"}],"article-number":"100082"}}